Bertil Abrahamsson
Overview
Explore the profile of Bertil Abrahamsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
110
Citations
1474
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beran K, Abrahamsson B, Charoo N, Cristofoletti R, Holm R, Kambayashi A, et al.
J Pharm Sci
. 2024 Nov;
114(2):660-680.
PMID: 39547650
According to the ICH M9 Guideline, the triazole antifungal voriconazole is a Biopharmaceutics Classification System (BCS) class II drug, being highly soluble at the highest dose strength but not at...
2.
Beran K, Abrahamsson B, Charoo N, Cristofoletti R, Holm R, Kambayashi A, et al.
J Pharm Sci
. 2024 Oct;
114(2):644-659.
PMID: 39454947
Lemborexant is a dual orexin receptor antagonist assigned to class II of the Biopharmaceutics Classification System (BCS). Thus, the ICH M9 Guideline excludes immediate-release (IR) solid oral dosage forms containing...
3.
Kambayashi A, Iida M, Ishihara M, Takahashi Y, Abrahamsson B, Charoo N, et al.
J Pharm Sci
. 2024 Aug;
113(11):3137-3144.
PMID: 39154736
The present monograph discusses the possibility of BCS-based biowaivers for immediate release pharmaceutical products containing raltegravir potassium, which is used to treat human immunodeficiency virus (HIV) infections. Raltegravir potassium can...
4.
Charoo N, Selvasudha N, Kath Z, Abrahamsson B, Cristofoletti R, Kambayashi A, et al.
J Pharm Sci
. 2024 Jun;
113(9):2981-2993.
PMID: 38857646
In this monograph, the potential use of methods based on the Biopharmaceutics Classification System (BCS) framework to evaluate the bioequivalence of solid immediate-release (IR) oral dosage forms containing fexofenadine hydrochloride...
5.
Parrow A, Kabedev A, Larsson P, Johansson P, Abrahamsson B, Bergstrom C
J Control Release
. 2024 Jun;
371:555-569.
PMID: 38844179
The use of animal experiments can be minimized with computational models capable of reflecting the simulated environments. One such environment is intestinal fluid and the colloids formed in it. In...
6.
Nystrom L, Mira I, Benjamins J, Gopaul S, Granfeldt A, Abrahamsson B, et al.
Mol Pharm
. 2023 Dec;
21(2):677-687.
PMID: 38133148
Omega-3 polyunsaturated fatty acids (-3 PUFA) are essential nutrients for human health and have been linked to a variety of health benefits, including reducing the risk of cardiovascular diseases. In...
7.
Plano D, Rudolph N, Saal C, Abrahamsson B, Cristofoletti R, Kambayashi A, et al.
J Pharm Sci
. 2023 Nov;
113(2):386-395.
PMID: 37951471
A Biopharmaceutics Classification System (BCS)-based biowaiver monograph is presented for isavuconazonium sulfate. A BCS-based biowaiver is a regulatory option to substitute appropriate in vitro data for in vivo bioequivalence studies....
8.
Zhou L, Bak A, Hyodo K, Abrahamsson B
Mol Pharm
. 2023 Oct;
20(10):4797-4799.
PMID: 37779466
No abstract available.
9.
Charoo N, Abdallah D, Ahmed D, Abrahamsson B, Cristofoletti R, Langguth P, et al.
J Pharm Sci
. 2022 Dec;
112(4):893-903.
PMID: 36581104
Levocetirizine, a histamine H1-receptor antagonist, is prescribed to treat uncomplicated skin rashes associated with chronic idiopathic urticaria as well as the symptoms of both seasonal and continual allergic rhinitis. In...
10.
Kambayashi A, de Meijer M, Wegman K, van Veldhuizen C, Abrahamsson B, Cristofoletti R, et al.
J Pharm Sci
. 2022 Dec;
112(3):634-639.
PMID: 36563854
This work describes the potential applicability of the BCS-based Biowaiver to oral solid dosage forms containing Levamisole hydrochloride, an anthelmintic drug on the WHO List of Essential Medicines. Solubility and...